Benlian P, de Gennes J L, Dairou F, Hermelin B, Ginon I, Villain E, Lagarde J P, Federspiel M C, Bertrand V, Bernard C, Bereziat G
Department of Endocrinology-Metabolism, Pitié Hospital, Paris, France.
Hum Mutat. 1996;7(4):340-5. doi: 10.1002/(SICI)1098-1004(1996)7:4<340::AID-HUMU8>3.0.CO;2-C.
Variability in the expression of monogenic lipid disorders may be observed in patients carrying the same DNA mutation, suggesting possible genetic or environmental interactions. Our objective was to investigate the genotype-phenotype relationships in two unrelated French patients with an aggravated expression of a dominantly inherited hypercholesterolemia. In probands, segregation analysis complemented by DNA sequencing identified heterozygous defective alleles and mutations on two nonallelic loci for two monogenic lipid disorders: familial hypercholesterolemia at the low density lipoprotein (LDL) receptor locus and familial defective apolipoprotein B-100 at the locus encoding its ligand, apolipoprotein B-100. The LDL-receptor missense mutations had been reported in French Canadians. The apolipoprotein B mutation was the Arg3500Gln founder mutation in Northern Europe. Probands had an unusual phenotype of aggravated hypercholesterolemia that was complicated with premature coronary arterial disease, although remaining responsive to lipid-lowering drugs. This phenotype was distinct from that observed in their heterozygous relatives and distinct from those observed in FH or FDB homozygotes. These cases refer to a new class of patients with digenic lipid disorders, defined by specific clinical features that result from the combined effects of two independent loci. Moreover, the observed phenotype of aggravated hypercholesterolemia gives further evidence that receptor and ligand play distinct roles in regulating LDL metabolism. Although uncommon, these cases give insight into the molecular mechanisms that underly the clinical variability of inherited hypercholesterolemia.
在携带相同DNA突变的患者中,可能会观察到单基因脂质紊乱表达的变异性,这表明可能存在基因或环境相互作用。我们的目的是研究两名无亲缘关系的法国患者的基因型-表型关系,这两名患者患有显性遗传高胆固醇血症的加重型。在先证者中,通过DNA测序进行的分离分析确定了两种单基因脂质紊乱在两个非等位基因位点上的杂合缺陷等位基因和突变:低密度脂蛋白(LDL)受体位点的家族性高胆固醇血症,以及编码其配体载脂蛋白B-100的位点上的家族性缺陷载脂蛋白B-100。LDL受体错义突变已在法裔加拿大人中报道。载脂蛋白B突变是北欧的Arg3500Gln始祖突变。先证者具有高胆固醇血症加重的异常表型,并伴有早发性冠状动脉疾病,尽管对降脂药物仍有反应。这种表型与他们的杂合亲属中观察到的表型不同,也与FH或FDB纯合子中观察到的表型不同。这些病例指的是一类新的双基因脂质紊乱患者,由两个独立位点的联合作用导致的特定临床特征所定义。此外,观察到的高胆固醇血症加重的表型进一步证明了受体和配体在调节LDL代谢中发挥着不同的作用。虽然不常见,但这些病例有助于深入了解遗传性高胆固醇血症临床变异性的分子机制。